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INTRODUCTION
PHARMACEUTICAL ANALYSIS
 Pharmaceutical analysis is an interdisciplinary subject and derives its principles from
various  branches  of  science  like  chemistry,  physics,  microbiology,  nuclear  science  and
electronics.
 Analytical determination is based on the measurement of some physical, chemical or
structural properties which are related directly or indirectly to the amount of desired constituent
present in the sample.
DRUG
Drug is referred to as medicine or medication, can be loosely defined as any chemical
substance intended for use in the medical, diagnosis, cure, treatment, or prevention of disease.
Drugs are the chemicals which are originated from either organic or inorganic. Some property of
medicinal agent is used to measure them qualitatively or quantitatively.
          The Pharmaceutical analysis is intended as a collection of all methods and procedures on
all possible pharmaceutical compounds. Both classical methods as well as instrumental methods
of analysis are required in quality control work. In modern pharmaceutical analysis separation
techniques such as HPLC, HPTLC and GC are employed nowadays for the analysis of drugs in
biological fluids, raw materials and dosage forms. The analysis of drugs by functional group
reactions may be required to provide sensitivity and selectivity purpose. The electro analytical
methods of analysis are advantageous to analyse certain group of pharmaceuticals but nowadays
the use of electrochemical methods are employed for detecting analytes in HPLC eluates.
 The electronic absorption spectroscopy in near UV and Visible wavelength regions is a
familiar  approach  in  the  analysis  of  active  pharmaceutical  ingredients  and  the  formulations
containing them. However it lacks the information of relationship of structure of analyte and the
environment of the molecule to the observed spectrum. Fluorescence spectroscopy is well known
and widely used technique in chemical analysis. This technique is limited in the quantification of
pharmaceuticals  possessing  fluorescent  character.  However  in  recent  days  non-fluorescent
molecules have been quantified employing indirect procedures such as chemical derivitization,
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tagging with a fluorescent molecule or by quenching ability of certain chemicals. Radio chemical
methods are other catogories of pharmaceutical  analysis employed for radio pharmaceuticals.
Radio immuno assay promises to be a powerful analytical technique for determining trace level
of drugs in complex biological matrices. The classical methods of analysis such as titrimetric
methods and gravimetric methods have been restricted in the determination of bulk inorganic
pharmaceuticals and excipients.
Quality  assurance  plays  a  important  role  in  determining  the  safety  and  efficacy  of
medicine.  Highly  specific  and  sensitive  analytical  techniques  are  important  in  the  design
development, standardisation and quality control of medicinal products. They are also important
in pharmacokinetics and drug metabolism studies. Modern instrumental methods are extremely
sensitive providing precise and detailed information from small samples of material. All drug
substances, their formulated dosage forms are subjected to strict quality assurance procedures.
Pharmacokinetic  studies  often  requires  measurements  in  the  microgram,  nanogram  or
picogram/ml range. Powerful coupled separative-detector system such as GC-MS, LC-MS, CE-
MS are used. The above systems are extremely versatile and expensive much valuable work can
be  still  accomplished  with  the  help  of  UV-spectrophotometry,  spectrofluorimetry  and
polarography.
ANALYTICAL CHEMISTRY:
It can be defined as the science and art of determining the composition of materials ,in
terms  of  the  elements  or  compounds  contained  either  qualitatively  or  quantitatively.(42) It  is
concerned with the identification of a substance, the elucidation of its structure and quantitative
analysis of its composition. (43) It is divided into two parts,
A . Qualitative analysis
B . Quantitative analysis
Qualitative Analysis:
               Qualitative analysis refers to the identity of the drug or identity of the elements radicals
or functional groups present in the compounds.
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Quantitative Analysis:
               Quantitative analysis involves determination of percentage purity of raw drugs or
quantity of drug present in the given dose of formulation. To achieve the above aspects different
analytical methods are needed.
TYPES OF ANALYSIS:
MODERN CLASSIFICATION:
1. Classical method of analysis
 Acid - Base titration
 Redox titration
 Complexometric titration
 Non aqueous titration
 Diazotisation titration
 Gravimetry
2. Instrumental method of analysis
 Electro analytical techniques
 Spectroscopic techniques
3. Separation technique
 Chromatography - hyphenated techniques
      4.   Biological / Microbiological method of analysis
 Microbiological assay
 Bio assay
5. Radiochemical methods
1. Classical method of analysis:
           It can be subdivided into two types titrimetry and gravimetry. Titrimetry method of
analysis involves use of standard reagent. The analyte in solution is made to react with
definite volume of the standard reagent of known concentration.
2. Instrumental method of analysis:
(a)  Electro analytical techniques involves,
 Potentiometry
 Amperometry
 Conductometry
 Coulometry
 
 SPECTROSCOPY:
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              Spectroscopy is the measurement and interpretation of electromagnetic radiation
absorbed,  scattered  or  emitted  by  atoms,  molecules  or  other  chemical  species.The
absorption  or  emission is  associated  with  changes  in  energy states  of  the interacting
chemical species and since each species has characteristic energy states, spectroscopy can
be used to identify the interacting species.
           The principle types of spectroscopic techniques are,
 Ultraviolet and visible spectroscopy
 Fluorescence and phosphorescence spectroscopy
 Atomic spectroscopy (emission and absorption)
 Infrared spectroscopy
 X-ray spectroscopy
 Nuclear magnetic resonance spectroscopy
 Electron spin resonance spectroscopy
                            
3. SEPARATION TECHNIQUES:
Chromatography:  
              Chromatography is a group of techniques for the separation of the compounds of
mixtures  by their continuous distribution between two phases one of which is moving
past the other .(1b)
                                  
  FLOW CHART  TYPES OF CHROMATOGRAPHY [6]
                                               CHROMATOGRAPHY
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Hyphenated - Techniques :
 Gas Chromatography - Mass Spectroscopy (GC - MS)
 Liquid Chromatography - Mass Spectrometry (LC - MS)
 Liquid Chromatography - Nuclear Magnetic Resonance
 Liquid Chromatography - Fourier Transform Infrared
ULTRAVIOLET AND VISIBLE ABSORPTION SPECTROPHOTOMETRY
           Spectroscopy is the study of interaction of matter with electromagnetic radiation.
A beam of photons constitute electromagnetic radiations (EMR) in which photons are
distributed in energy bundles. Based on wavelength, frequency and energy of radiation,
the electromagnetic spectrum is divided into following rays:
                              Cosmic rays
                              Gamma rays
                              X-rays
                              Ultra-violet rays
                              Visible rays 
                              Infrared rays
                              Microwave rays
                              Radio waves
            The UV region in electromagnetic spectrum is from 200 nm to 400 nm and the
visible region in electromagnetic spectrum is from 400 nm to 800 nm. The two laws
which govern the UV -Visible spectroscopy are Beer's law and Lambert's law.
            Beer's  law states  that  the rate  of  decrease  of  intensity of  radiation with
concentration of absorbing species is proportional to the intensity of incident radiation.
Dept. of  Pharmaceutical Analysis  5
Column
Chromatography
Paper 
Chromatography
Thin layer 
Chromatography
HPTLC HPLC 
Chapter 1                                                                                                            Introduction
The absorbance A, of a solution is defined as the logarithm to base 10 of the reciprocal of
the transmittance T, for monochromatic light, and is expressed by the equation:
                                     A = log10(I/T) = log10(I0/I)
where I    = The intensity of transmitted monochromatic light,
           I0   = The intensity of incident monochromatic light and T = I/I0
            In the absence of other physio-chemical factors, the measured absorbance (A) is
proportional to the path length (d) through which the light passes and to the concentration
(c) of the substance in accordance with the expression 
 A = cd
             where ε is the molar absorptivity when d is expressed in cm and c in moles per litre.
           The expression A(1%, 1 cm) representing the specific absorbance of a dissolved
substance  refers to the absorbance of a 1.0% w/v solution in a 1 cm cell and measured at
a defined wavelengh so that
A(1%, 1 cm) = 10ε/M
where M is the molecular weight of the substance being examined.
          The specific absorbance is therefore the notional absorbance of a 1-cm layer of a
1% w/v solution of the absorbing solute, its value at a particular wavelength in a given
solvent being a property of the solute. The absorbance of the solution is usually measured
in a cuvette with 1 cm path length.
           In measuring the absorbance of a solution at a given wavelength, the absorbance
of the reference cell and its contents should not exceed 0.4 and is preferably less than 0.2
when measured with reference to air at the same wavelength.
          The absorption spectrum is plotted with absorbance or function of absorbance as
ordinate against wavelength of function  of wavelength as abscissa. (8)
            Apparatus :
          Spectrophotometers suitable for measuring in the ultraviolet and visible range of
the spectrum consist of an optical system capable of producing monochromatic light in
the range 200 nm to 800 nm and a device suitable for determining the absorbance.
Instrument Components :
 Light source
 Monochromator
 Sample / Reference cells 
 Detector
 Signal processors and readout system
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             Light Source :
                        Tungsten Filament lamp - for production of visible radiation.
                  Hydrogen - Deuterium discharge lamp - for production of  UV radiation.
  
Monochromator :
             The various wavelength from light source are separated with a prism or grating and then
selected by slits such that the rotation of the prism causes a series of continuously increasing
wavelengths  to  pass  through  the  slits  for  recording  purposes.  The  selected  beam  is
monochromatic which is then divided into two beams of equal intensity.
  Sample / Reference cells :
             Sample / Reference can be contained in cells made of a material which is transparent
throughout the region under study. Glass cannot be used since it absorbs strongly in the ultra
violet region because glass are made up of alkali earth metals. Quartz are used in UV region.
Glass can be satisfactorily used in visible region.
Detectors :
             Photomultiplier tubes and photo diodes are the two important type of photo detectors.
For the determination of substances by spectrophotometric techniques, precise determinations of
the  light  intensities  are  necessary.  Photoelectric  detectors  are  most  frequently  used  for  this
purpose. They must be employed in such a way that they give response linearly proportional to
the light input and they must suffer from drift . (1b)
Signal processors and readoutsystem :
             A signal processors is an ordinarily an electronic device that amplifies the electric signal
from the detector. In addition it may alter the signal from ac to dc, change the phase of signal and
filter it to remove unwanted components. The signal processors may also be called on to perform
such mathematical operation on the signal differentiation,  integration or convert to logarithm.
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SPECTROFLUORIMETRY
Introduction:
             When the molecules  are  exposed to  the electromagnetic  radiation they exhibit
fluorescence. Fluorescence is a process of re-emission of radiation energy absorbed in the form
of visible or UV light.  In this process, the light emitted is always of longer wavelength than that
absorbed. In fluorescence, absorption and emission of light takes place in short time (10-12 to 10-9
seconds). The quantitative determination of fluorescence is the basis of fluorimetric analysis. (2)  
Figure No. 1   Spectrofluorimeter
Principle of fluorescence :
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                 A molecule in a ground state is considered to have three energy levels viz. rotational,
vibrational  and electronic.  When an electromagnetic radiation falls  on the molecule it  brings
changes into its changes into its  energy levels and they will go to excited state.  The excited
molecular species are extremely short-lived and deactivation occurs due to:
 Internal collisions
 Cleavage of chemical bonds, initiating photochemical reactions
  Re-emission as light (luminescence)
Figure No. 2
Molecules on excitation normally possess higher vibrational energy than they had in
the ground state.  This extra vibrational  energy is  lost  by collision,  after  which the molecule
returns to the ground state with the emission of light as fluorescence. Fluorescence is a rapid
process  occurring  within  10-6 to  10-9 seconds  of  the  excitation.  If  there  is  any delay in  the
emission of light is called as phosphorescence. The delay period may range from fraction of a
second  to  few  days.  Both  these  processes  of  re-emission  are  generally  designated  as
luminescence. (3)
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Factors Affecting Fluorescence :
F = 2.3 Io abc 
j
For a fixed set of instrumental (Io and b) and sample (a and 
j
) parameter,
the fluorescence is proportional to concentration.
                                     F = kc where k = 2.3 Ioab
j
There are number of factors which or directly or indirectly affect the fluorescence and decrease
its  intensity and sensitivity which is termed as "quenching".
1. Concentration :
                     Fluorescence is best in dilute solution. In concentrated solution the intensity of
fluorescence is reduced and is not quantitative. This is called as concentration quenching.
2. Quantum yield of  fluorescence (
j
):
j
 = no of photons emitted / no of photons absorbed
Highly  fluorescent  substances  have  
j
 values  near  to  unity,  which  shows  that  most  of  the
absorbed  energy is re-emitted as fluorescence. Non fluorescent substance have 
j
=0.
3. Intensity of Incident light :
                An increase in the intensity of light incident on the sample produces a proportional
increase in the fluorescent intensity. The intensity of incident light and sensitivity of fluorescence
measurement are increased by increasing the width of the excitation slit.
4. Oxygen :
                The presence of oxygen may interfere in two ways, by direct oxidation of the
fluorescent to non-fluorescent products, or by quenching of fluorescence.
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5. pH :
                  Alteration of pH brings in the ionized and non-ionized form of fluorogenic material.
6. Temperature and viscosity :
                An increase in temperature or decrease in viscosity is likely to decrease fluorescence
by deactivation of the excited molecules by collision. Low temperature and appropriate dilute
solution are necessary for quantitative analysis.
7.  Quenchers :
Collisional quenchers :
                 Collisional quenchers reduce fluorescence by dissipating absorbed energy as heat due
to collisions with the quenching species.
                 e.g. Quinine is highly fluorescent in 0.05 M Sulphuric Acid but non-fluorescent in 0.1
M Hydrochloric Acid or in presence of halide salt.
            Static quenchers :
                 Static quenchers form a chemical complex with the fluorescent substance and alter its
fluorescence characteristics.
                 e.g.   Caffeine reduces the fluorescence of riboflavin by static quenching.
Instrumentation :
  Two primary kind of instruments are used to measure the fluorescence
 Filter fluorimeter
 Spectrofluorometer
                 Instruments that measure the intensity of fluorescence are called fluorimeters. Those
that measure the fluorescence intensity at variable wavelength of excitation and emission and are
able to produce fluorescence spectra are called as Spectrofluorimeters. (1a) 
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Figure No. 3    Components of a spectrofluorimeter
1. Source of light :
 Mercury vapour lamp (or)
 Xenon-arc lamp
Providing light output from 190 - 1200 nm
Versatile and powerful
2. Filter and monochromator :
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           In spectrofluorometer, excitation and emission monochromators are used
       Excitation Monochromator :
           Provides a suitable radiation for excitation of the molecules
       Emission Monochromator :
            Isolate only the radiation emitted by the fluorescent molecule
3. Cuvettes/cells :
          Four sides polished cuvettes are used. Made up of borosilicate or quartz glass.
4. Detector :
          Photo multiplier tube (PMT) is used as detector.
Advantage :
• Standard device
• Large signal
• Fast rise time possible
Disadvantage :
High voltage required
Sensitive to magnetic field
           The light source produces light photons over a broad energy spectrum, typically ranging
from 200 to 900 nm. When photons falls on the excitation monochromator, which selectively
transmits light in a narrow range. The transmitted light passes through adjustable slit that control
magnitude and resolution by further limiting the range of transmitted light. The filtered light
passes in to the sample cell causing fluorescent emission by fluorophores with in the sample.
Emitted light  enters the emission monochromator,  which is positioned at  900 angle from the
excitation light path to eliminate background signal and minise noise due to stray light. Again the
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emitted  light  is  transmitted  through adjustible  slits,  finally  entering  the  PMT.  The  signal  is
amplified and create a voltage that is proportional to the measured emitted intensity. (7)
Advantages of fluorimetry :
 Hundred to thousands times more sensitive than absorbance techniques
 Possible to analyse sample in the nanogram to picogram level
                                  
VALIDATION
          Validation of an analytical method is the process by which it is established, by
laboratory  studies,  that  the  performance  characteristics  of  the  method  meet  the
requirements for the intended analytical applications. (37)
          Validation is not a method development tool and it does not make a method good
or efficient. (38)
          Validation is a team effort. It will involve people from various functions in the
plant. (39)
           Validation  is defined as follows by different agencies,
Food and Drug administration (FDA) (40) :
            Establishing documentation evidence, which provides a high degree of assurance
that  specific  process,  will  consistently  produce  a  product  meeting  its  predetermined
specification and quality attributes.
World Health Organization (WHO) :
             Action of providing that any procedure,  process,  equipment, material, activity,
or system actually leads to the expected results.
European Committee (41) :
             Action of providing in accordance with the principles of good manufacturing
practice that  any procedure,  process,  equipment,  material,  activity,  or  system actually
leads to the expected results. In  brief validation is a key process for effective quality
assurance.
Reasons for Validation :
             There are two important reasons for validating assays in the pharmaceutical
industry. The first, and by for the most important, is that assay validation is an integral
part of the quality-control system. The second is that current good manufacturing practice
regulation requires assay validation.
 Method Validation parameters :
1. Accuracy
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2. Precision
3. Repeatability
4. Intermediate precision
5. Reproducibility
6. Range
7. Specificity
8. Linearity
9. Limit of detection ( LOD )
10.  Limit of quantitation ( LOQ )
11.  Ruggedness
12.  Robustness
           1.  Accuracy :
         The closeness of agreement between the value, which are accepted either as a
conventional true value or accepted reference value and the value found. The accuracy of
the method is  tested by recovery studies at  three different  levels by adding a known
amount of pure drug to the pre-analysed formulation of definite concentration.
2.  Precision :
         The precision of an analytical procedure expresses the closeness of agreement
between a series of measurements obtained from multiple sampling of the homogenous
sample under the prescribed conditions. ICH divides precision into three types.
1. Repeatability
2. Intermediate precision
3. Reproducibilty
3. Repeatability :
        Repeatability is the precision of method under the same operating conditions over a
short  period of  time. One aspect  of this is  instrumental precision.  A second aspect  is
sometimes termed intra-assay precision and  involves multiple measurements of the same
sample by the same analyst under the conditions.
4. Intermediate precision :
        Intermediate precision is the agreement of complete measurements when the same
method is applied many times within the same laboratory. This can include full analysis
samples and standards.
5. Reproducibility :
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        Reproducibility examines the precision between laboratories and is often determined
in collaborative studies or method transfer experiments.
        Precision often is expressed by the standard deviation or relative standard deviation
of the data set.
6. Range :
        The range of a method can be define as upper and lower concentration for which the
analytical  method  has  adequate  accuracy,  precision  and  linearity.  The  range  of
concentration examined will depended on the type of method and its use.
7. Specificity :
        Specificity is the ability to assess unequivocally the analyte in the presence of
components, which may be expected to be present. Assuring specificity is the first step in
developing and validating a good method. If specificity is not assured, method accuracy,
precision  and  linearity  all  are  seriously  compromised.  Method  specificity  should  be
reassessed continually during validation and subsequent use of method.
8. Linearity :
        The linearity of an  analytical procedure is its ability to obtain test result, which are
directly proportional to concentration of analyte  in the sample. Linearity can be assessed
by  performing  single  measurements  at  several  analyte  concentration.  A  linearity
correlation coefficient above 0.999 is acceptable for most methods, especially for major
components in assay method.
9. Limit of detection (LOD) :
        The limit of detection an individual analytical procedure is the lowest amount of
analyte  in  the sample which can detected but  not  necessarily quantitated as  an exact
value. The limit of detection (LOD) may be expressed as;
                                    LOD = σ 3.3 / S
 Where
  σ  = the standard deviation of the response
  S  = the slope of the calibration curve of the analyte
10. Limit of quantitation (LOQ) :
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        The limit of quantitation of an analytical procedure is the lowest amount of analyte
in  the  sample  which  can  be  quantitatively  determined  with  suitable  precision  and
accuracy.
Limit of quantitation (LOQ) can be expressed as;
                                 LOQ = σ10 / S
 Where,
 σ  = standard deviation of the response
 S  = slope of the calibration curve of the analyte
11. Ruggedness :
        Method ruggedness is defined as the reproducibility of result when the method is
performed under actual use conditions. This includes different analysts, laboratories and
instruments. Method ruggedness may not be known when a method is first developed, but
insight is obtained during subsequent use of that method.
12. Robustness :
       The concept of robustness of an analytical procedure has been defined by the ICH as
“a method of its capacity to remain to unaffected by small, but deliberate variation in
method parameters”. The robustness of the method was tested by changing wavelength
range, scanning speed and solvents composition.
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2. DRUG PROFILE
NIFEDIPINE
2.1 NOMENCLATURE
Structure :
Chemical Formula :
 3,5-dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
CAS Registry number :
21829-25-4
Molecular Formula :
17 18 2 6C H N O
Molecular Weight :
346.335 g/mol
Category :
Antianginal and Antihypertensive
ATC code :
C08CA05
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2.2 PHYSICAL PROPERTIES :
Nifedipine is a yellowish crystalline powder. It is stored at room temperature. It melt in
the range of 171 - 175  oC. It is insoluble in water, freely soluble in ethanol, methanol, and in
acetone.
2.3 DOSAGE FORMS :
Formulations  currently  available  are  Nifedipine  in  ordinary  capsules  (5  and  10
milligrams),  soft  gel  capsules  (5  mg and 10  milligrams),  coated  tablets  (10,  30,  40  and  60
milligrams) and extended release tablets (5, 10, and 20 milligrams).
2.4 PHARMACOLOGY :
Indication :
            Nifedipine is indicated in angina (chest pain ), high blood pressure and abnormal heart
rhythms. Nifedipine works by relaxing blood vessels.
Mechanism of Action :
            Nifedipine is a calcium channel blocker. It has two mechanism of action. They are,
• Relaxation and Prevention of Coronary Artery Spasm
• Reduction of oxygen utilization
Relaxation and Prevention of Coronary Artery Spasm :
            Nifedipine dilates the main coronary arteries and coronary arterioles, both in normal and
ischemic regions, and is a potent inhibitor of coronary artery spasm, whether spontaneous or
ergonovine-induced.  This  property  increases  myocardial  oxygen  delivery  in  patients  with
coronary artery spasm, and is  responsible  for  the effectiveness  of   nifedipine in  vasospastic
angina. 
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Reduction of Oxygen Utilization :
                Nifedipine regularly reduces arterial pressure at rest and at a given level of exercise by
dilating  peripheral  arterioles  and  reducing  the  total  peripheral  resistance  (afterload)  against
which the heart works. This unloading of the heart reduces myocardial energy consumption and
oxygen requirements and probably accounts for the effectiveness of nifedipine in chronic stable
angina.
Contraindication :
                It is contraindicated in patients with very low blood pressure or shock due to heart
problems and hypersensitivity.
Special Precaution :
   It should  not be given to patients over the age of  65 and above and pregnancy cases.
Adverse Effects :
  The adverse drug reactions are headache,  feeling of lightheadedness, sleepy, blurred
vision, and lowered concentration, hot flushes, headache, sudden change of position may cause
dizziness,  nausea and vomiting,  constipation or diarrhea,  swelling  of  extremities,  and  gum
problems.
Drug Interactions :
Alcohol                              -    It will increase drowsiness
Grapefruit                          -   This will increase the incidence of side effects
Cyclosporin                       -   It increases risk for gingivitis
Beta-adrenergic blockers   -   It increases risk for congestive heart failure, severe lowering of 
blood   pressure and further aggravation of chest pain might arise
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2.5 PHARMACOKINETICS :
Absorption :
 Nifedipine is rapidly and fully absorbed in oral administration.
 Nifedipine is detectable in serum 10 minutes after oral administration. Peak blood level
occurs approximately in 30 minutes. 
Distribution :
92-98 % of Nifedipine is bound to serum protein.
Metabolism :
The drug is  bio  transformed in liver.  The principal   metabolite  is   2,6-dimethyl-4-(2-
nitrophenyl)-5-methoxycarbonyl-pyridine-3-carboxylic acid .
Excretion :
The elimination half life is approximately 2 hours.
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LITERATURE REVIEW
 SPECTROSCOPIC METHODS :
 R K Sheladia  et al., [2011]   have reported spectrophotometric determination of nifidipine in
bulk and tablet dosage form. The method was based on reduction of the nitro group of nifedipine
to amino group by treatment with zinc dust and hydrochloric acid. The reduced molecule was
diazotized  with  sodium  nitrite  and  coupled  with  Bratton-Marshall  reagent  N-(1-naphthyl)
ethylenediamine  dihydrochloride.  The  absorbance  was  measured  for  the  magenta  coloured
derivative at 430 nm. The method was validated in terms of precision, specificity and lineatity
range. 9
R.Revathi  et al., [2010] developed a  spectroscopic determination of nifedipine   using 40 %
sodium salicylate solution as hydrotropic solubilizing agent. The drug showed λ‐max at 350 nm
and beer’s law was obeyed in the concentration range of 20 – 100 µg/ml. The result of  analysis
for tablet dosage form obtained by the proposed method was compared with pharmacopoeial
method. The proposed method was statistically validated as per ICH guidelines. The percentage
content and percentage recoveries estimated for Nifedipine marketed tablet formulations were
close to 100 with low %RSD. 10
Sathis Kumar Dinakaran et al., [2013] have studied and reported a simple, economic, accurate
absorption ratio method  for the simultaneous estimation of atorvastatin calcium and nifedipine
HCl in bulk and tablet dosage form. Methanol was used as a diluent. The absorption maxima
were  observed  at  237 nm  and  297 nm  which  were  selected  based  on  overlap  spectra  of
atorvastatin calcium and nifedipine HCl.. The proposed method was validated. 11
Sheikha  M.Al-Ghannam  et  al., developed  a  spectrofluorometric  determination  of
nicardipine,nifedipine and isradipine in pharmaceutical  preparations and in  biological  fluids.
The method was based on the reduction of nicardipine, nifedipine and isradipine with Zn/HCl
and measuring the fluorescence intensity  of reduction product (λem/λex) at 460/364, 450/393 and
446/360  nm,  respectively.  The  factors  affecting  the  development  of  the  fluorophore  and  its
stability  were  studied  and  optimized.  The  effect  of  some surfactants  such  as  β-cyclodextrin
(βCD), carboxymethylcelullose (CMC), sodium dodecyl sulphate (SDS) and triton ×-100, on the
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fluorescence  intensity  was   also  studied.  The  fluorescence  intensity-concentration  plots  of
nicardipine, nifedipine and isradipine were rectilinear over the ranges 0.4–6.0, 0.2–4.0 and 0.1–
9.0 µg ml−1 with detection limits of 0.0028, 0.017 and 0.016 µg ml−1, respectively. The proposed
method  was  successfully  applied  to  commercial  tablets  containing  the  compounds  and   the
percentage recovery agreed well with those obtained using the official methods. The method was
further extended to the in vitro determination of the compounds in spiked human plasma and
urine samples. 12
B.Hemmateenejad  et  al., [2008] have reported a simple,  accurate,  sensitive and economical
colorimetric procedure for the estimation of amlodipine besylate and nifedipine, both in pure and
dosage forms. The method was based on the reduction of iron(III)  by the studied drugs and
subsequent interaction of iron(II) with ferricyanide to form prussian blue. The reaction developed
through a slow kinetics and completes in about 10 min. Both initial slope and fixed time methods
were used to derive calibration graphs.  The resulted calibration equations were linear  in the
concentration ranges of 1.0-20.0 and 3.0-19.0 µg ml-1 for AML and NIF, and the detection limits
were 0.10 and0.19 µg ml-1, respectively. Seven replicate analyses of solutions containing three
different levels of each drug resulted in very low relative error of prediction (less than 1.6%) and
relative standard deviation (less than 4%) confirming accuracy and precision of the proposed
method. 13
Sable Kunal et al., [2012] have described UV-Spectrophotometric method for the simultaneous
determination  of  nifedipine  and  atenolol  in  combined  dosage  form as  well  as  in  laboratory
mixture was studied under this paper. Nifedipine and Atenolol are used in combined dosage form
for Cardiovascular System Diseases. The developed method was validated as per ICH guidelines.
The stability study of combined dosage form was carried out by using the IR spectrum of both
the drug. 14
Normaizira Hamidi et al., [2008] have reported  analysis of nifedipine content in transdermal
drug   delivery  system  using  non-destructive  visible  spectrophotometric  technique. The
applicability of visible spectrophotometry technique as a tool to determine the drug content of
polymeric film was investigated.  Hydroxypropylmethycellulose (HPMC) was selected  as  the
matrix  polymer and nifedipine as the model drug. Blank and nifedipine-loaded HPMC films
were  prepared using the  solvent  evaporation method.  The  absorbance  spectra  of  these  films
under the visible wavelengths between 400 and 800 nm were assessed and compared against the
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drug content values obtained by means of the conventional destructive UV spectrophotometry
technique.  The  results  indicated  that  the  absorbance  values,  attributed  to  nifedipine,  at  the
wavelengths of 545, 585, 638 and 755nm were significantly correlated to the drug content values
obtained using the chemical assay method (Pearson correlation value: r ≥ 0.990 and p < 0.01).
The  visible  spectrophotometry  technique  was   potentially  suitable  for  use  to  determine  the
nifedipine content of films. The samples were  recoverable from test and analysis of the entire
batch of samples was  possible without the need of solvents and chemical reagents. 15
Joaquim C.G. Esteves da Silvab et al., [2010]  have investigated fluorescence derivatization
reaction  and  quantification  of  the  antihypertensor  nifedipine.  A fluorescence  derivatization
reaction based on the reaction of Nifedipine with o-phthalaldehyde after a previous reduction of
the nitro group to a primary amine and photooxidation of the dihydropyridine to pyridine was
optimized.  Chemometric  data  analysis  was  done  by parallel  factor  analysis  2  (PARAFAC2)
multivariate  calibration  model  of  a  three  way data  structure  obtained  by  the  acquisition  of
complete excitation-emission matrices (EEMs) of a Nifedipine fluorescent derivate following a
standard  addition  method.  The  results  found  in  the  quantification  of  Nifedipine  in  different
pharmaceutical  formulations  were  compared  with  the  official  US  Pharmacopeia  high
performance  liquid  chromatography -  ultraviolet  method  (USP HPLC-UV).  For  each  of  the
pharmaceutical formulations, a fortified sample was also analysed. Good results were found with
the PARAFAC2 spectrofluorimetric methodology. Generally, similar PARAFAC2 models were
needed  for  the  adequate  decomposition  of  the  unfortified and  fortified  samples  of  the same
pharmaceutical formulation. 16
Nafisur  Rahman  et  al., [2005]  have  described  two  simple  ,  sensitive  and  economical
sepctrophotometric  methods  were  developed  for  the  determination  of  nifedipine  in
pharmaceutical formulations. Method A was based on the reaction of the nitro group of the drug
with potassium hydroxide in dimethyl sulphoxide (DMSO) medium to form a coloured product,
which absorbed maximally at 430 nm. Method B used oxidation of the drug with ammonium
molybate and subsequently reduced molybdenum blue was measured at 830 nm. Beer’s law was
obeyed  in  the  concentration  range  of  5.0-50.0 and  2.5-45.0 µg ml−1 with  methods  A and  B
,respectively.  Both  methods  have  been  successfully  applied  for  the  assay  of  the  drug  in
pharmaceutical  formulations.  No  interference  was  observed  from  common  pharmaceutical
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adjuvants.  The reliability and the performance of the proposed methods were established by
point and interval hypothesis tests and through recovery studies.17
Olajire Aremu Adegoke et al., [2012] have described a new sensitive colorimetric method for
nifedipine  following  azo  dye  formation  with  4-carboxyl-2,6-dinitrobenzenediazonium  ion
(CDNBD).  Judging  from  the  various  generic  brands  currently  available,  this  research  was
conceived as a means of developing an alternative cost-effective and readily adaptable method
for  the  assay  of  nifedipine  in  tablets  and  for  which  official  high  performance  liquid
chromatographic technique may not be readily available. Nifedipine was reduced with Zn/Hcl
reduction system and then the diazo coupling reaction was carried out with the CDNBD reagent
to generate a new azo adduct with optimal wavelength at 470nm representing a bathochromic
shift relative to nifedipine, reduced nifedipine and CDNBD reagent. Optimal temperature and
time for coupling were selected as 500C and 15 minutes. A linear response was observed over2.9-
14.5microgram per ml of nifedipine. The developed spectrophotometric method is of equivalent
accuracy (p>0.005) with USP 2007 HPLC method.18
Sayed M.Derayea et al., [2013]  have reported spectrophotometric method for determination of
five  1,4-dihydropyridine  drugs  using  N-Bromosuccinimide  and  Indigo  carmine  dye   by
determining residual of NBS through its ability to bleach the colour of the used dye. Beer’s law
was obeyed  in  concentration range  1.25-13.00µg/ml.  Good correlation coefficient  was found
between  absorbance  value  and  concentrations.  Limit  of  detection  ranged  from  0.141  to
0.500µg/ml. This method was applied to the analysis of dosage forms, % recovery ranged from
97.31 to 99.4% without interference from common excipients. The comparision by student’s t-
test and variance ratio F-test showed no difference between the proposed and official methods.19 
Mohamed  Abo  EI-Hamd  et  al., [2010]   have   investigated  spectrophotometric  and
spectrofluorimetric methods for determination of 1,4-dihydropyridine (1,4-DHP) drugs based on
the  oxidation  of  the  investigated  1,4-DHP drugs  with  acidic  KMnO4(method  I)  or  Ce  (IV)
(method II).  First method was based on decrease in colour of permanganate solution due to the
presence of the studied drug and measured at 525nm. Second method was based on monitoring
the fluorescence of the produced cerium (III) at emission 355nm and excitation at 255nm. The
method was validated according to International Conference of Hormonization guidelines. This
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method was applied for the determination of drugs in commercial tablets and capsules. The result
of the proposed procedures were statistically compared with reference method obtained.20
Y. Awad Uday  et al., [2011] have developed a  simple, selective, rapid, precise, sensitive and
accurate HPLC method  for the estimation of nifedipine using methanol and water (70:30 v/v) as
mobile phase; pH was adjusted to 3.0 with orthophosphoric acid. Detection was carried out using
UV detector at 238 nm. The method was carried out on a Shim-Pack CLC, ODS (C-18), 5 µ
column and dimension of column was 250×4.6mm. The retention time of nifedipine was 3.401
min. The developed method was validated in terms of linearity, precision, accuracy, precision,
limit of detection and limit of quantitation. The method was found to be linear in the range of 5-
40 µg/ml.21 
Ravin Jugade et al., [2011] have established A simple and rapid differential pulse polarographic
method was developed for the trace determination of Nifedipine. A well-defined single peak with
Ep value of -0.51 V was obtained in 0.1M acetate buffer (pH 5.0). The linearity was valid up to
5×10  -5 M  (r =0.9995) with minimum detection limit of 3.5×10  -8M. Precision of the method
developed  was   implied  from the  values  of  relative  mean deviation,  standard  deviation and
coefficient of variation, which were  2.05%, 1.1 and 3.2% respectively. Marketed formulations of
Nifedipine  have  been  analyzed  by  calibration  and  standard  addition  methods.  Recovery
experiments have been found to be quantitative and analysis to determine the mass per tablet was
obtained within ±0.2% of the expected value.22 
Bengi Uslu et al., [2010] have studied and reported  a square wave voltammetry (SWV), which
was  presented  in  this  mini  review,  had  a  several  advantages  such  as  high  speed,  increased
analytical sensitivity and relative insensitivity to the presence of dissolved oxygen. Also it was
an electrochemical technique used in analytical applications and fundamental studies of electrode
mechanism. This paper delivered  both the underlying theory and the practical guidance needed
to apply square wave techniques and also provided a wide collection of data for the description
of diverse tendencies that characterized several electrochemical reactions analyzed by SWV. This
review summarized some of the recent developments and application of  direct  and stripping
SWV for drug compounds in their dosage forms and biological samples.23
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Dragica  Zendelovska et  al., [2006] have  studied a  HPLC method for  the determination  of
nifedipine  in  human plasma followed after  solid-phase  extraction. A selective,  sensitive and
accurate high-performance liquid chromatographic method has been developed, validated and
applied for determination of nifedipine in human plasma samples. The method involved solid-
phase  extraction  on  C18 cartridges.  The  chromatographic  separation  was  accomplished  on  a
Lichrocart Lichrospher 60 RP select B column with a mobile phase composed of 0.020 mol/L
KH2PO4 (pH 4.8) and acetonitrile (42:58, v/v). UV detection was set at 240 nm. The calibration
curve was linear in the concentration range of 5.0–200.0 ng/mL for nifedipine in plasma and the
limit of quantification was 5.0 ng/mL.24 
Arindam Mukhopadhyay et al., [2012] have studied  LCMS/MS method for the determination
of Nifedipine and Nifedipine D6. They were extracted from the plasma by precipitation method
and  then  seperated  on  a  reverse  phase  chromotography  using  the  mobile  phase  mixture  of
ammonium acetate and methanol at a flow of 1.0 ml/min. The analytes were detected in API
4000 mass spectrometer in the positive atmospheric pressure chemical ionization (APCI)  mode
with mutiple reaction monitoring (MRM). The MRM transitions were monitored by following
m/z for parent ion 347.2 & daughter ion 315.1 (nifedipine), and m/z 353.2 & daughter 318.2
(nifedipine D6). A linear calibration plot of nifedipine was achieved in the concentration ranges
of 1.558 ng/ml to 360.561 ng/ml. Mean recovery was 93.2%. The assay was specific, precise,
accurate and reproducible.25
Madhuri Ramteke et al., [2010] have development an accurate and precise high performance
thin layer chromatographic method for simultaneous estimation of atenolol and nifedipine in
their combined dosage form was  developed. The study employed Kieselghur 60,  GF254 on
aluminium foil and a mobile phase comprising cyclohexane: methanol: ethyl acetate: ammonia
(5:1.5:3:0.5 v/v).  The detection was carried out at  230 nm. The linear  detector  response for
atenolol  was  observed  between  5.7-18.9  
/g mLm
.  The  recovery  study  was  carried  out  by
standard addition method. The results  of recovery were 99.76  
±
 0.216, 100.72  
±
0.216  for
atenolol and 100.04 
±
1.069,99.89 
±
 1.058 for nifedipine.26
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Shubhini A. Saraf et al., [2010] A rapid and sensitive RP-HPLC method has been developed for
the purpose of analysis of antihypertensive: nifedipine (NF), antidiabetic: nateglinide (NG) and
hypolipidemic: lovastain (LT) drugs simultaneously in cardiovascular polypill based synthetic
ternary mixture. Analysis was performed on 
18C
(125 
´
4.6 mm id, 5
m
m particle) column with
acetonitrile- 10mM phosphate buffer (pH 3.5) 60:40 (v/v) as mobile phase, started at a flow rate
of 1 mL 
1min -
continued for 4 min and further 6 min at a flow rate of 2 mL 
1min -
. UV detection
was  performed  at  208  nm  for  NF,  NG  and  at  236  nm  for  LT.  The  run  time  under  these
chromatographic conditions was less than 10 min. The method was linear in the range of 0.125-
8.0   
gm
 
1mL-
 for  NG  and  LT.  Acceptable  precision  and  accuracy  were  obtained  for
concentrations over the standard curve ranges. The sensitivity of the method, as the limits of
detection (LOD) and quantification (LOQ) for each active ingredient was also determined. The
validated method was successfully applied to the analysis of synthetic mixture and of  three
drugs. The percentage recoveries obtained were 100.23% for NF, and 100.93% for LT.27
Hisham S. Abou-Auda et al., [1999] have studied sensitive, selective and reproducible reversed-
phase high-performance liquid chromatographic method was developed for the determination of
nifedipine in human plasma with minimum sample preparation. The method was sensitive to 3
ng/ml in plasma, with acceptable within and between day reproducibilities and linearity (r2>0.99)
over a concentration range from 10-200 ng/ml. Acidified plasma samples were extracted using
diethylether  containing  diazepam  as  internal  standard  and  chromatographic  separation  was
accomplished on C18 column using a mobile phase consisting of acetonitrile, methanol and water
(35:17:48, v/v). The within-day precision ranged from 2.22 to 4.64% and accuracy ranged from
102.4-106.4%.  The  day-to-day  precision  ranged  from  2.34-7.07%  and  accuracy  from  95.1-
100.1%.  The  relative  recoveries  of  nifedipine  from  plasma  ranged  91.0-107.3%   whereas
extraction recoveries were 88.6-93.3 %. Following eight 6-week freeze-thaw cycles, nifedipine
in plasma samples proved to be stable with accuracy ranging from 0.64 to 3.0 % and precision
ranging from 3.6 to 4.15%. Nifedipine was also found to be photostable for at least 120 min in
plasma, 30 min in blood and for 60 min in aqueous solutions after exposure to light. The method
was  sensitive  and  reliable  for  pharmacokinetic  studies  and  therapeutic  drug  monitoring  of
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nifedipine in humans after the oral administration of immediate-release capsules and sustained-
release tablets to five healthy subjects.28
M.L. Avramov Ivic  et al., [2013]  have examined the electrochemical  behaviour of inclusion
complexes of nifedipine (Nif) and amlodipine (Aml), a long-acting calcium channel blockers
dihydropyridine  (DHP)  class,  with  
b
-cyclodextrin  (
b
CD)  and  (2-hydroxypropyl)-  
b
-
cyclodextrin (HP
b
CD), was examined using cyclic and square wave voltammetry in 0.05 M
NaHCO3 and phosphate buffer (pH=11) on a gold electrode.  The voltammograms showed  a
single irreversible  anodic  wave with  the current  controlled by adsorption.  It  was found that
phosphate buffer was favourable in the electrochemical activity of both complexes of Nif with
the linear dependency of the oxidative currents on their concentrations. In phosphate buffer, only
HP
b
CD-Aml complex showed linear dependency of the oxidative apparent currents maximum
of  all  the  examined  complexes  in  both  electrolytes  were  shifted  to  the  positive  direction
compared to their standards. In addition, the value of anodic currents decreased.29
Albetro S. Pereira et al., [2008] have analyzed the fragmentation of dihydropyridine calcium-
channel antagonists were compared by electrospray ionization (ESI) and atmospheric pressure
photonization (APPI). The results demonstrated  that in ESI the preferred ionization process is in
positive mode, with the mass spectra of [M+H]+ showing base peak ions probably formed by loss
of  alcohols  from carboxyl  groups.  Conversely,  in  APPI,  a  high  intense  peak  is  observed  in
negative mode due to deprotonated molecule [M+H]-
 
after two serial 1,2-hydride shifts leading to
a rearranged deprotonated molecule [M-H]-.  These ions suffered another 1,2-hydride shifts to
produce a nitro-phenyl product ion of m/z 122. The APPI was also used to develop a method for
the quantitation of dihydropyridines (e.g., nifedipine) in human plasma.30
Morteza Pirali  et al., [1999]  have performed a experiment using a simple normal phase high
performance liquid chromatography (HPLC) method for determination of nifedipine in human
plasma. The method was based on ultraviolet detection at 235 nm and acidic plasma extraction
by a mixture of dichloromethane (30%) and n-hexane (70%) using nimodipine as an internal
standard.  The system was stabilized with the use of n-hexane (80%), chloroform (17%) and
methanol (3%) as mobile phase. The assay was linear for 3 ng/ml plasma. The reproducibility of
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the method was satisfactory.  The procedure could be  used effectively to quantitative in the
drug.31
Luis J. Nunez-Vergara  et al., [2002] have studied a gas chromatography/mass spectrometry
(GC/MS)  method  for  the  qualitative  and  quantitative  determination  of  the  calcium-channel
anatagonists C-4-substituted 1,4-dihydropyridines and their corresponding N-ethyl derivatives,
was presented.  Also,  the electrochemical  oxidation and the reactivity of the compounds with
alkyl  radicals  derived from 2,2-azobis-(2-amidinopropane) were monitored by GC/MS. Mass
spectral  fragmentation patterns for the C-4-substituted 1,4-dihydropyridine parent drugs  were
significantly different from those of their oxidation products, generated either by electrochemical
oxidation  or  by  reaction  with  alkyl  radicals.  However,  for  N-ethyl-1,4-dihydropyridine
compounds  it  was  not  possible  to  detect  the  final  products  (pyridinium  salts)  using  these
experimental conditions.32
R.L.C. Sasidhar et al., [2012] have developed  a simple precise and economical reverse phase
high performance liquid chromatographic method  for the estimation of atenolol and nifedipine
simultaneously in combined dosage form. The method was developed using agilent  ODS C18
column with a mobile phase constituting of methanol: acetonitrile: phosphate buffer (60:20:20)
finally adjusted to pH 3.0 with o-phosporic acid at a flow rate of 1.0 ml/min and detection was
carried out at 235 nm. The selected chromatographic conditions were found to separate atenolol
(Rt:  2.80 min)  and  nifedipine  (Rt:  4.40  min)  having a  resolution  of  12.307.  The  developed
method was validated for linearity, accuracy, precision, LOD, LOQ, robustness and for system
suitability parameters as per ICH guidelines. Linearity for atenolol and nifedipine were found in
the range of 5-25 ig/ml and 2-10 ig/ml, respectively. The percentage recoveries for atenolol and
nifedipine ranged from 99.38-100.56% and 99.16 - 99.71%, respectively. The proposed method
could be used for routine analysis of atenolol and nifedipine in their combined dosage forms.33
V. Venkata Rajesham et al.,  [2008]  have developed a simple and sensitive high performance
liquid chromatographic method for the simultaneous estimation of simvastatin (lipid lowering
agent)  and nifedipine (calcium channel  blocker)  in  rat  plasma and also to  calculate  possible
pharmacokinetic parameters of these drugs after oral administration in hyperlipidemic condition.
The plasma samples were precipitated with methanol and after centrifugation (5000-6000 rpm
for 10 min), the acetonitrile was added to the ethanol and the organic mixture was taken to near
dryness by a steam of nitrogen at room temperature. The mobile phase consisted of acetonitrile
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and water. The drug was monitored at 237nm. The run time was 15 minutes. The good linearity
was found to be in the range of 0.05 to 40 
/g mlm
 for two drugs. This developed method was
rapid,  sensitive,  reproducible and successfully applied to the measurement of  simvastain and
nifedipine in rat plasma for studying of pharmacokinetic interaction between these two drugs.34
XingJie Guo et al., [2007] have determined a sensitive atmospheric pressure chemical ionization
liquid chromatographic-mass spectrometric (APCI-LC-MS) assay with positive ion mode was
developed for the determination of nifedipine in human plasma. In this method, nifedipine was
extracted from human plasma using diethyl ether with dimethoxanate as the internal standard.
Analysis was achieved on a BDS C18  column with methanol-water (66:34, v/v) as the mobile
phase.  Sustained-release  nifedipine  tablets  from  Disha  (test,  Weihai,  China)  from  GuoFeng
(reference, Qingdao, China) were evaluated following a single 20 mg oral dose to 20 healthy
volunteers. Bioequivalance between the products was determined by calculating 90% confidence
intervals (90% CI) for the ratio of Cmax  , AUC0-t  and  
0AUC -¥
values for the test and reference
products, using logarthmic transformed data. The 90% confidence  intervals for the ratio of Cmax
(86.6 - 105.2%), AUC0-t (97.8 - 110.9%) and  
0AUC -¥
(96.5 - 110.4%) values for the test and
reference  products  were within  the  interval  (80  -  125% for  AUC, and 70 -  143% for  Cmax)
proposed by state of food and drug administration [SFDA, 2005 guidence for bioavailability
studies for chemical drug products in human being, China, p.19]. It was concluded that the two
sustained-release nifedipine tablets are bioequivalent in their rate and extent of absorption and
thus may be used interchangeably.35
C.M.  Andersen  et  al., [2003]  have  expreimented  a  dedicated  investigation  and  pratical
description  of  how  to  apply  PARAFAC  modelling  to  complicated  fluorescence  excitation-
emission  measurements.  The  steps  involved  in  finding  the  optical  PARAFAC  model  were
described  in  detail  based  on  the  characteristics  of  fluorescence  data.  These  steps  included
choosing the right number of components, handling problems with missing values and scatter,
detecting variables influenced by noise and identifying outliers. Various validation methods were
applied in order to ensure that the optimal model has been found and several common data-
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specific  problems  and  their  solutions  were  explained.  Finally,  interpretations  of  the  specific
models  were  given.  The  paper  could  be  used  as  a  tutorial  for  investigating  fluorescence
landscapes with multi-way analysis.36 
Dept. of Pharmaceutical Analysis  33
Chapter 4                                                                 Introduction to present study  
INTRODUCTION TO PRESENT STUDY
                 UV-Visible spectrophotometric method and quenchofluorimetric methods were
adopted for present work for the quantification of nifedipine in tablet formulation.
UV-Visible spectrophotometric determination of nifedipine:
                On the examination of the chemical structure of nifedipine revealed the presence of
aromatic rings with –NHCOCH3 and nitro substituent which are strongly electron withdrawing
groups. Nifedipine as expected from its structure, exhibits light absorbing property in UV-Visible
region having λ‐max at 330 nm in methanolic solution which was made use for its quantitative
method by absorptiometric method.
Quenchofluorimetric determination of nifedipine:
Nifedipine  did  not  exhibit  any  native  fluorescence  because  of  the  strong  electron
withdrawing  substituents.  Therefore  the  drug  was  examined  whether  it  has  any  quenching
property.
A number  of  fluorescent  molecules  were  tried  as  fluorescent  probe  (donor).  Quinine
sulphate,  N-1  Napthyl  Ethylene  Diamine,  and  fluorescein were  the  fluorescent  probes  tried.
Among them, the reagent `Quinine sulphate’ was found to be more suitable because of their
similarity in the solubility of drug and the donor in the same media methanol. The fluorescent
intensity of quinine sulphate was stable and maximum in methanol. Hence this probe moiety was
selected.
First the linear relationship was established between concentration of quinine sulphate
and fluorescence intensity. From this, the optimum concentration of quinine sulphate solution
was  selected  for  the  quenchofluorimetric  method.  The  nifedipine  standard  solution  and  test
solution were prepared. Then mixture of quinine sulphate and nifedipine, with quinine sulphate
concentration fixed and the concentration of nifedipine were varied. The fluorescence intensity
for  the mixture  were  measured  at  the  characteristic  excitation wavelength.  The  fluorescence
intensity  diminishes  linearly  for  the  quinine  sulphate  with  the  increasing  concentration  of
nifedipine.  The  quenching  caused  by  known  concentration  of  the  drug  (Nifedipine)  was
compared with that produced by test preparation.
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The characteristics of Quinine sulphate was briefly given below,
QUININE SULPHATE
It was obtained from the bark of various species of cinchona including succirubra, pavon
red cinchona officinalis, Linn
Chemical Structure :
Molecular Weight            : 782.96
Molecular Formula          : (C20H24N2O4)2.H2SO4.2H2O
Melting point                   : 235 OC
Description                      : Fine, white,  needle like crystals, odorless, darkens on         
                                           exposure to light.
Solubility                         : Slightly soluble in water
                               Slightly soluble in ethanol and in boiling water
                               Practically insoluble in ether 
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Use  of quinine sulphate : It is used in the treatment of malaria,  leg cramps, and used to treat
falciparum malaria.
Light  absorption  property  :  Quinine  Sulphate  is  a  light  absorbing  as  well  as  a  fluorescent
compound. It exhibits light absorption in the range of 200 nm - 400 nm in methanol with the
maxima at 280 nm and 334 nm. The fluorescence spectrum of quinine has excitation maxima at
350 nm and emission maxima at 450 nm.
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AIM OF PRESENT STUDY
                Nifedipine is an anti hypertensive drug. Nifedipine is official in IP, BP, and USP.
Determination of nifedipine raw material in I.P is based on HPLC separation on ODS (5 µm)
with mobile phase 55:36:9 volumes of water, methanol and acetonitrile and detected at 235nm.
The finished product formulation  have been quantitated by UV spectrophotometric method at
350 nm and using methanol as medium.
                Literature review was made thoroughly on the above drug. Different analytical
methods have been reported such as UV-Vis spectrophotometry, RP-HPLC, HPTLC, LC-MS,
and GC/MS and polarographic methods for the determination of nifedipine in its dosage form
and in combination with other drugs and in biological matrix.
                The present work is the development of modified quenchofluorimetric method. The
determination  of  nifedipine  has  been  made  by an  indirect  fluorimetric  method  based  on  its
quenching  ability  upon  an  fluorescent  probe.  In  this  technique  a  suitable  fluorescent  probe
moiety quinine  have  been  tried  to  determine  the  drug.  The  method utilizes  decrease  of  the
fluorescence intensity of the probe moiety by the selected drug. The linearity exists between the
concentrations of the active drug to the degree of fluorescence quenched upon the probe moiety
quinine sulphate .
                 To arrive at the accuracy of the proposed method, its assay result was compared with
that  obtained  by  UV-Visible  spectrophotometric  method.  The  later  method  involved
measurement of absorbance of the drug nifedipine in methanol at its  λmax. The assay method has
been validated.
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METHODOLOGY
Quenchofluorimetric determination of  nifedipine using Quinine  Sulphate as  a  probe
moiety :
Apparatus/ Instruments used :
Spectrofluorimeter RF - 5301 PC
Analytical electronic weighing balance (Shimadzu)
Chemical used :
Sulphuric acid AR grade
Distilled water
Methanol HPLC grade
Tablet Formulation :
Nifedipine Tablets - 10 mg (Alkam)
           Brand name - Nifedine
METHOD DEVELOPMENT
Establishment of various parameters for the drug nifedipine :
Selection of excitation and emission maxima :
Preparation of 0.05M H2SO4 :
2.8 ml of H2SO4 was diluted to 1000 ml with distilled water to produce 0.05M H2SO4.
Preparation of Quinine Sulphate Solution :
0.04g of Quinine Sulphalte was accurately weighed and transferred into 100 ml of
standard flask. The sample was dissolved in small volume of 0.05 M H2SO4  and the volume
was made up to 100 ml (400 
/g mlm
). 5 ml of this solution was pipetted into 50 ml standard
flask and diluted with 0.05 M H2SO4 (40 µg / ml )   From this 5 ml of the solution was
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pipetted into 50 ml standard flask and diluted with methanol (4 
/g mlm
). From this, 3 ml of
the solution was diluted to 25ml with methanol. The concentration of quinine in final dilution
was  0.48  µg  /  ml.  This  solution  was  used  to  obtain  the  fluorescence  excitation  and
fluorescence emission spectrum of quinine sulphate.
Dilution chart of Quinine Sulphate Solution :
0.04g Quinine Sulphate      *       100 ml (400
/g mlm
)
                                                          
                                                    5ml     *     50 ml (40
/g mlm
)
                                                                         
           5ml     0             50ml (4
/g mlm
)
                                                                                            3ml    0      25 ml (0.48µg/ml)    
                                                                                                                               
       
 *        0.05M H2SO4 ,0- methanol
Excitation and emission spectrum of Quinine Sulphate :
                Quinine Sulphate solution was prepared with methanol to get a final concentration
of  0.48 
/g mlm
.  The solution was used to scan in the wavelength range of 290 - 410 nm for
excitation and 390 - 510 nm for emission spectrum. From the spectrum of Quinine Sulphate,
the optimum wavelength for excitation and emission were selected and found to be at 350 nm
and 450 nm respectively. The data for excitation and emission spectrum are presented in table
number 1,
Dept. of Pharmaceutical Analysis  38
Chapter  6 Methodology
Table no 1 Data for Fluorescence excitation and emission spectrum of Quinine Sulphate
Wavelength for
Excitation (nm)
Fluorescence
Intensity
Wavelength for
emission (nm)
Fluorescence
Intensity
290 191.006 390 75.801
300 284.697 400 136.663
310 387.656 410 250.872
320 404.506 420 393.603
330 442.202 430 509.555
340 563.573 440 587.188
350 613.878 450 610.778
360 527.667 460 582.284
370 318.106 470 511.851
380 130.567 480 424.246
390 40.985 490 336.846
400 14.039 500 257.921
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410 6.732 510 189.657
Graph no 1 Fluorescence excitation and emission spectra for Quinine Sulphate 
0
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Ex.flu
Em.flu
From the spectra it was found that excitation maxima is at 350 nm and emission maxima is at
450 nm.
Selection of pH :
          A stock solution of  Quinine Sulphate was prepared in  methanol with a
concentration of  400 µg /ml. This was stepwise diluted in methanol to get a concentration of
4 µg/ml. 3ml of this solution was diluted with different medium. 
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Dilution chart :
40mg Quinine sulphate                      100 ml (400
/g mlm
)
       5ml  methanol 50ml (40
/g mlm
)
               5ml  methanol       50ml (4
/g mlm
)
          3 ml                3ml                 3ml                 3ml                3ml                  3ml
         25ml               25ml             25ml               25ml                25ml               25ml
Table no 2 Data for effect of pH upon fluorescence
Probe Moiety Excitation
wavelength
(nm)
Emission
wavelength
(nm)
Reagents F.I
0.05 M H2So4       924
Methanol       576
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0.05MH2SO4     Methanol
0.1M  Acetic 
Acid 
Acetate 
buffer  pH 
4.5
Ammonium 
acetate buffer 
pH6.8
0.01 M Borax 
pH 9.1
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Quinine Sulphate
(0.48
/g mlm
)
          350         450
0.1M acetic acid (pH-2.8 )       676
Acetate buffer (pH-4.5)       550
Ammonium  acetate  buffer
(pH-6.8)
      530
0.01 M Borax(pH-9)       50
The Fluorescence Intensity was maximum in 0.05M H 2SO4.
Effect of temperature upon Fluorescence Intensity :
0.04g of  Quinine  sulphate  was  accurately weighed  and transferred  into  a  100  ml
standard volumetric flask and made up with0.05 M H2SO4 acid. From this 5 ml was pipetted
and transferred into a 50 ml standard volumetric flask and made up with 0.05 M H2SO4.
Further dilution of 5 ml was pipetted out and transferred into 50  ml standard volumetric flask
and made up with methanol. The final concentration of Quinine sulphate  was found to be
0.48
/g mlm
.  The  effect  of  temperature  upon  Fluorescence  Intensity  was  determined  by
maintaining the last solution at different temperatures such as 15oC, 20oC, 25o, 30oC & 35oC.
Dilution chart :
0.04g      *       100ml (400
/g mlm
)
*           0.05 M H2SO4
                         5ml        *       50ml (40
/g mlm
) 0 Methanol
      5ml      0         50ml (4
/g mlm
)
                                                                    3ml       0        25ml (0.48
/g mlm
)
Data for effect of temperature upon Fluorescence Intensity :
                                                      Table no 3
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Probe Moiety Ex. Wavelength
(nm)
Em. Wavelength
(nm)
Temperature
(oC)
       FI 
Quinine sulphate
(0.48
/g mlm
)
           350        450
         15      575.464
         20      570.293
         25      563.512
         30      550.493
Construction of analytical curve for Quinine Sulphate :
 A stock solution of Quinine Sulphate with the concentration of 400 µg /ml was prepared in
methanol . From this, the solution was stepwise diluted to obtain a series of standard solution
ranging in the concentration of 0.08 µg/ml to 0.64 µg/ml. The final dilution was made with
methanol  as  medium.  The  samples  were  excited  at  the  wavelength  of  350  nm  and
fluorescence  emission  measured  at  450  nm  .  The  calibration  curve  was  constructed  by
plotting  concentration  of   Quinine  Sulphate  versus  fluorescence  intensity.  The  data  for
standard curve has been given in table no 2.
Dilution Chart :
0.04g Quinine Sulphate      0            100 ml (400
/g mlm
)  
                                                      5ml      0           50ml (40
/g mlm
)
                                                                            5ml     *      50ml (4
/g mlm
)
                   0.5 ml               1 ml                   2 ml                  3 ml                   4 ml
   *                       *                      *                        *                        *
                 25 ml                  25 ml               25 ml          25 ml                  25 ml
           (0.08
/g mlm
)   (0.16
/g mlm
)  (0.32
/g mlm
)  (0.48
/g mlm
)  (0.64
/g mlm
)
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*         methanol
0              0.05 M H2SO4
   Table no 4 Data for calibration curve of Quinine Sulphate using Methanol as medium
S. No Concentration ( µg/ml ) Fluorescence Intensity
    1                      0.08                           109
    2                      0.16                           221
    3                      0.32                           438
    4                      0.48                           660
    5                      0.64                           876
                                Graph no 2  Calibration curve of Quinine Sulphate
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                                         Correlation Coefficient = 0.999989
LINEARITY :
Procedure for study of quenching property of Nifedipine :
                 A calibration curve for  the study of quenching by Nifedipine was constructed by
adopting the following steps.
                Nifedipine has been shown to posses quenching property upon Quinine Sulphate.
The degree of quenching by the drug nifedipine upon the fluorescence of Quinine Sulphate
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was studied by preparing a series of concentration of nifedipine with constant amount of
Quinine Sulphate.
                A stock solution of nifedipine was prepared in methanol (1000 µg / ml ). The stock
solution was diluted ten times with methanol to obtain the concentration of 100 µg / ml .
From this, different  volume of the solution 0 to 5ml were transferred into different 25ml
standard volumetric flask . To each flask, 3ml of Quinine Sulphate solution (4 µg / ml ) was
added. Each mixture was diluted to the mark with methanol. After the final dilution , each
flask  contain  constant  concentration  of  Quinine  Sulphate  of  0.48  µg  /  ml  and  the  drug
nifedipine ranges from 0 to 20 µg / ml.
                    The difference in the fluorescence intensity between pure quinine solution and
that of mixture containing Quinine  and nifedipine was taken as the amount of quenching.
Dilution chart for fluorescence quenching by Nifedipine :
0.025g nifedipine     0         25 ml (1000
/g mlm
)
                                           
                                        2.5ml     0         25ml (100 
/g mlm
)
     0 ml              1 ml                 2 ml                3 ml                    4 ml                 5 ml
         *                    *                      *                     *                        *                        * 
    25 ml            25 ml              25 ml               25 ml                25 ml                 25 ml
(0
/g mlm
)    (4
/g mlm
)    (8
/g mlm
)     (12
/g mlm
)     (16
/g mlm
)       (20
/g mlm
)
*          3 ml of Quinine Sulphate solution of 4
/g mlm
0                    Methanol
                              Table no 5  Data for calibration curve for Nifedipine
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S. No Concentration of Nifedipine
(
/g mlm
)
No. of units quenched
                 1                       4                    25
                 2                       8                    51
                 3                      12                    76    
                 4                      16                    100
                 5                      20                    125
     
Graph no 3  calibration curve for Nifedipine
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                                            Correlation Coefficient = 0.9999113
Limit of detection (LOD) :
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 The limit of detection an individual analytical  procedure is  the lowest amount of
analyte in the sample which can detected but not necessarily quantitated as an exact value.
The limit of detection (LOD) may be expressed as;
                                    LOD = σ 3.3 / S
 Where
  σ  = the standard deviation of the response
  S  = the slope of the calibration curve of the analyte
Limit of quantitation (LOQ) :
             The limit of quantitation of an analytical procedure is the lowest amount of analyte in
the sample which can be quantitatively determined with suitable precision and accuracy.
Limit of quantitation (LOQ) can be expressed as;
                                 LOQ = σ10 / S
 Where,
 σ  = standard deviation of the response
 S  = slope of the calibration curve of the analyte
Table no 6 Data for LOD and LOQ
S. No Name of the drug LOD LOQ
1 Nifedipine 0.03083 0.093449
Assay :
Preparation of standard Nifedipine solution :
A standard  solution  of  pure  nifedipine  with  the  concentration  of  400  µg/ml  was
prepared  in  methanol.  From  this,  6ml  of  the  solution  was  pipetted  into  25ml  standard
volumetric  flask,  and  the  volume was  made up  with  methanol.  3ml  of  the  solution  was
pipetted from the above solution into another 25ml standard flask. To this 3ml of Quinine
Sulphate solution was added. The mixture was made up to 25ml with methanol.
Dilution chart for standard Nifedipine solution :
0.025 g of Nifedipine     *       25ml (400 
/g mlm
)
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                                               6 ml      *       25ml (96
/g mlm
)
 *           Methanol                                        3+3ml QS         *       25 ml (11.5
/g mlm
)
Preparation of test solution of Nifedipine :
                  Average weight of the tablet was computed from the weight of 20 tablets .The
tablets were powdered in a mortor and pestle.
                  An amount of tablet powder was accurately weighed so as to contain 0.01g of pure
nifedipine, transferred to a 25ml standard volumetric flask. The active ingredients present in
the tablet was extracted by shaking the powder in 15ml of methanol for about 15minutes. The
volume was made up with more methanol and mixed well. The solution was clarified by
filtration. 6ml of clear filtrate was diluted to 25ml with methanol. 3ml of this solution was
pipetted in to a 25ml standard flask. To this, 3ml of quinine sulphate solution (4 µg/ml ) was
added. The mixture was made up to 25ml.
Dilution chart for test solution of Nifedipine :
Tablet powder equivalent            *         25 ml (400
/g mlm
)
to 0.01g nifedipine
                                                               6ml     *         25ml (96
/g mlm
)
*           methanol
QS         Quinine Sulphate                                           3 + 3ml QS     *        25ml (11.
/g mlm
)
Preparation of control solution :
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  A control solution was prepared by omitting the drug and diluting 3ml of Quinine Sulphate
solution to 25ml with methanol. The fluorescence intensity was measured by exciting the
solution at 350 nm and measuring fluorescence emission at 450 nm.
Dilution chart for control :
                  3 ml of Quinine Sulphate      *         25 ml
                   *                  methanol
             The instrument was set at excitation wavelength 350 nm and emission wavelength at
450 nm. The fluorescence was measured for the standard, test and control solution.
             The data of assay of nifedipine tablet is given in table no 4 
Assay calculation :
             The content of drug present in each tablet and average weight calculated by using
following formula.
Fluorescence quenched by test               wt of std      dilution factor         avg wt of tablet
Fluorescence quenched by standard       wt of test
Table no 7  Data for assay of tablet
Brand name - Nifedine
S. No Wt of std
(g)
FI
Quenched
Wt of tablet
powder (g )
FI
Quenched
Content of
nifedipine (g)
1   
0.025 74
0.2303 73.2 0.01016
2 0.2302 73.4 0.01019
3 0.2310 73.0 0.01014
4 0.2305 72.8 0.01011
5 0.2300 72.6 0.01008
                                                                                                                       % RSD = 0.64 %
Interference studies :
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       The excipients most likely present in the tablet formulation were used to know its
fluoresceing nature and quenching ability. Each of the commonly used excipients are talc,
lactose and magnesium stearate and they were taken in the same proportion as found in tablet
formula.  First  the  extract  of  the  excipients  was  separately  prepared  in  methanol.  After
clarification by filtration, it was examined for their fluorescence character. Then the effect of
quenching upon the probe moiety Quinine Sulphate was also studied by carrying out the
experiment similar to that of assay of the formula.
        The result for interference study is given in table no 8
Table no 8 Data for interference studies
S. No Probe moiety Probe Moiety
with excipients
FI. Quenched
        1
Quinine
Sulphate
QS + talc Nil
        2 QS + lactose Nil
        3 QS+ magnesium
Sterate
Nil
       From the above result, we clearly know that the excipients do not posses fluorescence or
they quench the fluorescence of Quinine sulphate.
Recovery Studies :
Procedure :
       Recovery studies are performed to know that the experimental procedure is free from
interference. Recovery studies were carried out at three different spiking levels namely 50%,
100%, and 150%. The active ingredient in tablet powder, spiked with pure drug was extracted
with small volume of methanol and the volume was made up to 25ml and it was stepwise
diluted with methanol and in the final dilution 3ml of quinine sulphate was incorporated and
diluted to 25ml. The experimental procedure for the recovery studies is similar to that  of
assay procedure for tablets. To compute the % of recovery a standard solution of nifedipine
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was also prepared. The degree of quenching was measured for the blank, standard preparation
as well as the test preparation containing nifedipine present in the formulation spiked with
known amount of nifedipine. The concentration of quinine sulphate in each of final dilution
at each spiked level is 0.48 µg/ml. The blank solution containing quinine with 0.48 µg/ml
was also prepared. A standard solution of nifedipine was prepared and the concentration of
nifedipine in final solution was 11.5 µg/ml.
         The scheme of dilution for three different spiking levels are shown in following tables,
Dilution chart for Recovery studies :
a) Dilution for standard :
0.015 g of nifedipine      *       25 ml
                                                4 ml      * 25ml
                                                   
                                                                       3+3ml QS    *       25ml (Conc. of NF 11.5µg/ml)
b) Spiking at 50% level
   0.23g tablet powder
   (equivalent to 0.01g )  +
   0.005g of spiked pure nifedipine         *       25 ml 
               
                                                              
                                                             4ml    *        25ml
                                                                              3+ 3ml QS      *      25ml                
                                                                                                    (Total NF 11.5µg/ml)
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c) Spiking at 100% level
 0.23g tablet powder    
( equivalent to 0.01g )   +
0.01g of spiked pure nifedipine     *          25ml 
           
                                                                 3ml   *        25ml
                     
                                                                                  3+3ml QS   *         25ml
                                                                                                                   (Total NF 11.5µg/ml)
d) Spiking at 150% level 
0.115 g tablet powder
(equivalent to 0.005g ) +
0.01g of spiked pure Nifedipine      *          25ml
                                                                       4ml        *       25ml
                                                                                              3+3ml QS     *      25ml
                                                                                                       (Total NF 11.5µg/ml)
* methanol
QS   Quinine Sulphate solution (0.48 µg/ml)
Recovery studies for Nifedipine
Table no 9 Data for recovery studies at 50 % level
S.
No
Wt of
std
(g)
Conc. of
std NF
(µg/ml)
FI
Quenched
Wt of
tablet
powder
(g)
Amount
of NF
spiked
( g )
Total
conc after
spiking
FI
Quenched
%
Recovery
   1 0.2302       74 100%
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0.015    11.5       74    0.005   11.5
   2 0.2303       73 98.6%
   3 0.2300       74 100%
   4 0.2305       73.1 98.78%
   5 0.2300       73 98.6%
 
Table no 10 Data for recovery studies at 100 % level
S.
No
Wt of
std (g)
Conc. of
std NF
(µg/ml)
FI
Quenched
Wt of
tablet
powder
(g)
Amount
of NF
spiked
( g )
Total
conc after
spiking
FI
Quenched
%
Recovery
   1
0.015     11.5       74
0.2301
   0.01   11.5
      72.7 98.24%
   2 0.2309       72.8 98.37%
   3 0.2300       74.0 100%
   4 0.2308       73.0 98.64%
   5 0.2306       72.7 98.24%
Table no 11 Data for recovery studies at 150 % level
S.
No
Wt of
std (g)
Conc. of
std NF
(µg/ml)
FI
Quenched
Wt of
tablet
powder
(g)
Amount
of NF
spiked
( g )
Total
conc after
spiking
FI
Quenched
%
Recovery
   1
0.015      11.5       74
0.1154
   0.01   11.5
      73.4 98.24%
   2 0.1154       73.0 98.37%
   3 0.1159       73.4 100%
   4 0.1150       73.0 98.64%
   5 0.1155       73.5 98.24%
ROBUSTNESS :
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               The Robustness is a measure of method capacity to remain unaffected by small,
deliberate variations in method parameters and provides an indication of method reliability
during normal use.
Change of Analytical Excitation and Emission wavelength :
The standard solution, control solution and test solution of Nifedipine were prepared
as per the tablet assay procedure. The degree of quenching was measured at 3 different sets of
excitation and emission wavelength and the content of tablet powder was determined. The
data for the study on robustness has been given in the table no 9. Assay of tablet was done at
the  analytical  wavelength  350  nm  as  excitation,  450  nm  as  emission.  The  analytical
wavelength was changed towards shorter and longer wavelength. The analytical wavelength
were shifted at ± 5nm for excitation and emission wavelength and % RSD was calculated. 
Data for Assay of Nifedipine tablet at different wavelengths
 Excitation wavelength- 350 nm and Emission wavelength- 450 nm 
Table no 12 Data for assay of nifedipine at analytical wavelength
S. N o Wt of std
(g)
FI
Quenche
d
Wt of tablet
powder (g )
FI
Quenched
Content of
nifedipine(g)
    1   
    0.025
       74
      0.2303      73.2      0.01016
    2       0.2302      73.4      0.01019
    3       0.2310      73.0      0.01014
    4       0.2305      72.8      0.01011
    5       0.2300      72.6      0.01008
    % RSD = 0.64 %
Excitation wavelength- 345 nm and Emission wavelength- 445 nm
Table no 13 Data for assay of nifedipine at shorter wavelength
S. No Wt of std
(g)
FI
Quenched
Wt of tablet
powder (g )
FI
Quenched
Content of
nifedipine
(g)
    1   
    0.025
       71
      0.2301      72.4     0.01048
    2       0.2309      71.0     0.01028
    3       0.2300      72.0     0.01042
    4       0.2308      71.0     0.01028
    5       0.2306      71.6     0.01036
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    % RSD= 0.85%
For Excitation wavelength- 355 nm and Emission wavelength- 455 nm
Table no 14 Data for assay of nifedipine at longer wavelength
S. No Wt of std
(g)
FI
Quenched
Wt of tablet
powder (g )
FI
Quenched
Content of
nifedipine (g)
    1   
    0.025
       70.2
      0.2300      70.0      0.01025
    2       0.2306      69.8      0.01022
    3       0.2305      70.0      0.01025
    4       0.2302      70.1      0.01026
    5       0.2300      70.3      0.01029
% RSD= 0.24 %
RUGGEDNESS :
          Ruggedness can be defined as the intrinsic resistance to the influences excerted by
operational variable. The ruggedness of the method is the degree of precision of test results
obtained  by  analysis  of  the  samples  under  a  variety  of  normal  test  conditions,  such  as
different analysts, instruments and columns.
Change of analyst :
The same procedure for assay of Nifedipine tablet was repeated by another analyst.
Dilution chart for standard solution :
25mg pure Nifedipine       *          25ml (1000
/g mlm
)
                                                     2.5ml      *       25ml (100
/g mlm
)
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                                                                            3ml      *      25ml (12
/g mlm
)
                                                                             +
                                                                             3 ml Quinine Sulphate
Dilution chart for tablet powder :
0.23g of powder             *                  25ml (400
/g mlm
)
                                                            6ml      *      25ml (96
/g mlm
)
                                                            3ml      *       25ml (11.5 
/g mlm
)
*            methanol          +
                                                                                 3 ml Quinine Sulphate
Table no 15 Data for assay of tablet by analyst I
S. No Wt of std
(g)
FI
Quenched
Wt of tablet
powder (g )
FI
Quenched
Content of
nifedipine (g)
    1   
    0.025
       74
      0.2303      73.2      0.01016
    2       0.2302      73.4      0.01019
    3       0.2310      73.0      0.01014
    4       0.2305      72.8      0.01011
    5       0.2300      72.6      0.01008
                                                                                                               % RSD = 0.64%
Table no 16 Data for assay of tablet by analyst II
S. No Wt of std
(g)
FI
Quenched
Wt of tablet
powder (g )
FI
Quenched
Content of
nifedipine (g)
    1   
    0.025
       76.5
      0.2305      76.0      0.01021
    2       0.2306      76.4      0.01026
    3       0.2309      75.6      0.01015
    4       0.2303      76.5      0.01028
    5       0.2300      76.2      0.01024
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                                                                                                                % RSD = 0.46%
                                     
 Precision :
         Precision is the measure of the degree of repeatability of analytical method under
normal operation and is normally expressed as % RSD for the statistically significant number
of samples.
           Three terms are widely used to describe the precision of a set of replicate data
including SD, Coefficient of variation and standard error of  mean.
 Standard deviation (SD)= 
xx
√∑¿ )
                                                   n-1
Where ,
             x – Observed value
             x  - Arithmetic mean
             n – Number of observations
The square of standard deviation is called variance. The precision is assessed by co-efficient
of variation which is related to standard deviation.
Coefficient of variation (% RSD ) =   
SD
x
x100
Where ,
             SD – standard deviation
               x  – Arithmetic mean
Standard Error of mean (SEM) =  
SD
√n
Where ,
       SD – standard deviation
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       n – Square root of number of observation
Table no 17  Data for precision study
S. No Brand name Standard
Deviation
Coefficient of
variation (%RSD)
Standard Error
of Mean (SEM)
    1 Nifedine 0.03826 0.42 0.01913
UV Spectrophotometric Determination of Nifedipine Using Methanol
 Instruments Used :
UV- visible double beam Spectrophotometer (Perkin Elmer EZ 301)
Analytical electronic weighing balance (Shimadzu)
Chemicals Used :
Methanol - S.D. Fine Chemicals, Mumbai
Tablet Formulation :
Nifedine Tablets -10 mg
METHOD DEVELOPMENT
Establishment of various parameters for the drug nifedipine :
Selection of λ‐max :
Preparation of Standard Stock Solution :
Standard stock solution was prepared by weighing 20 mg of nifedipine pure drug and
transferring into a 50ml flask. The drug was dissolved in small volume of methanol and  the
volume was made upto 50 ml with methanol to get a concentration of 400
/g mlm
.
Preparation of Standard Solution :
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From the standard stock solution, pipetted out 2 ml solution, into a 25 ml standard
volumetric flask, and the volume was made upto 25 ml with methanol to get a concentration
of 32 
/g mlm
.
Dilution Chart :
0.02 gm of pure Nifedipine       *     50 ml (400
/g mlm
)
 *          Methanol                           2 ml       *       25 ml (32
/g mlm
)
Selection of Wavelength:
The standard solution of nifedipine was scanned in the  region of  200 - 400 nm to get
absorption spectrum of the compound. The drug exhibited a maximum absorbance at 330 nm
in methanol and hence this wavelength was selected for further studies. The absorbance data
were presented in table  no 1
           
Table no 18  Data for the absorption Spectrum of Nifedipine in Methanol
S. No Wavelength Absorbance
1 200 1.824
2 210 1.369
3 220 1.136
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4 230 1.361
5 240 1.423
6 250 0.911
7 260 0.502
8 270 0.359
9 280 0.317
10 290 0.298
11 300 0.309
12 310 0.363
13 320 0.406
14 330* 0.418
15 340 0.410
16 350 0.388
17 360 0.354
18 370 0.313
19 380 0.264
20 390 0.204
21 400 0.138
Graph No.4  Absorption spectrum for Nifedipine in Methanol
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Table No.19  System Parameters
                                                        WAVELENGTH SCAN
                     Data Mode                     Absorbance
                    Start WL (nm)                         400.00
                    Stop WL (nm)                         200.00
                    Scan Speed (nm/min)                         100
                    Slit Width (nm)                         1.5
                    Path Length (nm)                         10.0
Construction Of Calibration Curve :
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0.025 gm of nifedipine pure drug was accurately weighed and transferred into 25 ml
standard volumetric flask. The volume was made up to 25 ml with methanol. From this 5ml
was pipetted out into a 50 ml standard flask and the volume was made up to 50 ml with
methanol. From this solution different aliquots ranging from 2 - 10 ml were transferred into a
series of 25 ml standard volumetric flask. The volume were made up with methanol. The
absorbance of the solution were measured at wavelength 330nm. The scheme of dilution for
the preparation of series of standard solution was presented below and the data for calibration
curve is given in table no 3
Dilution Chart Of Calibration Curve For Nifedipine :
      25 mg of pure nifedipine      *     25 ml (1000
/g mlm
)
     *
                2 ml              4 ml                  6 ml                    8 ml                      10 ml
   *   *                      *                          *                         *
                25 ml            25 ml              25 ml                    25 ml                    25 ml
             (8
/g mlm
)     (16
/g mlm
)    (24
/g mlm
)     (32
/g mlm
)    (40
/g mlm
)
*               Methanol
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Table No.20 Data For Calibration Curve Of Nifedipine Using Methanol
S. No Concentration (µg / ml ) Absorbance
1 8 0.101
2 16 0.204
3 24 0.304
4 32 0.404
5 40 0.500
Graph No. 5   Calibration Curve of Nifedipine Using Methanol
0 5 10 15 20 25 30 35 40 45
0
0.1
0.2
0.3
0.4
0.5
0.6
Correlation Coefficient = 0.999926
Limit of detection (LOD) :
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 The limit of detection an individual analytical  procedure is  the lowest amount of
analyte in the sample which can detected but not necessarily quantitated as an exact value.
The limit of detection (LOD) may be expressed as;
                                    LOD = σ 3.3 / S
 Where
  σ  = the standard deviation of the response
  S  = the slope of the calibration curve of the analyte
Limit of quantitation (LOQ) :
             The limit of quantitation of an analytical procedure is the lowest amount of analyte in
the sample which can be quantitatively determined with suitable precision and accuracy.
Limit of quantitation (LOQ) can be expressed as;
                                 LOQ = σ10 / S
 Where,
 σ  = standard deviation of the response
 S  = slope of the calibration curve of the analyte
Table No. 21  Data for LOD and LOQ
  S. No   Name of the drug          LOD          LOQ
     1        Nifedipine      0.0152114      0.0460952
Assay :
Preparation Of Standard Nifedipine Solution :
About  0.02  gm  of  pure  Nifedipine  powder  was  accurately  weighed  and
transferred into a 50 ml standard volume flask. The drug was dissolved in a small volume of
methanol and the volume was made up to the mark with methanol. From this solution, 2 ml
of solution was pipetted  into a 25 ml volumetric flask and the volume was made up with
Methanol.
Dilution Chart for Standard Nifedipine solution :
0.02 gm of Nifedipine    * 50 ml (400
/g mlm
)
                                                   2 ml     *     25 ml (32
/g mlm
)
Dept. of Pharmaceutical Analysis  64
Chapter  6 Methodology
*                 Methanol
Preparation of Test Nifedipine Solution :
Twenty tablets were weighed and the average weight of the tablet was calculated.
The tablets were powdered with a help of mortar and pestle. The tablet powder equivalent to
about 0.023g of the active component was accurately weighed and transferred into a 50 ml
standard volumetric flask. About 30 ml of methanol was added and  the flask was kept in a
warm water bath for extraction of the drug. The liquid was cooled and the final volume was
made up with methanol.  The solution was clarified by filtration through Whatmann filter
paper. 2 ml of filterate was pipetted into a 25ml standardflask  and diluted with methanol to
the mark.
Dilution Chart For Test Nifedipine Solution :
         Tablet powder                     *           50 ml (400 µg/ml )
          0.550 gm  
2 ml     *       25 ml ( 32 µg/ml )
*                    Methanol
Calculation :
Absorbance  of the standard and test solution were measured at 330 nm against methanol as
blank. The content of nifedipine in a tablet of average weight was calculated as follows
 The content of Nifedipine is present in each tablet of average weight is
Abs of test Wt of Std   2                     50                     25              Avg wt of tablet
Abs of std             50                 25           wt of tab powder            2                                      
       The data for the assay of nifedipine tablet is given in tablet no 5
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Table No. 22  Data for Quantitative Determination of Nifedipine tablet
Label claim - 10 mg
S.
No
Wt of  Std
(gm)
Abs of std Wt of Test
(gm)
Abs of
test
Avg Wt
(gm)
Content of
tab (gm)
% Label
claim
1
   0.0203     0.414
0.5500 0.489
 0.22753
0.00991 99.19
2 0.5501 0.497 0.01007 100.7
3 0.5500 0.496 0.01006 100.6
4 0.5502 0.489 0.00991 99.15
5 0.5500 0.496 0.01006 100.6
                                                                                                                   % RSD = 0.84 %
Excipient Studies :
    Excipient studies was done with the excipient that are  normally encountered in tablet
formulation.  The  excipients  were  selected  as  talc,  lactose  and  magnesium  stearate.  The
excipient was accurately weighed and extracted with in methanol for 10 minutes and the
procedure was followed as per the tablet assay. The absorbance of the solution was measured
at a wavelength of 330 nm using methanol as a blank.
Table No. 23  Data for Interference Studies
S. No Name of excipient Wt of excipient (g) Absorbance
    1 Talc
           0.5500       0.000    2 Lactose
    3 Magnesium stearate
Recovery Studies :
Procedure :
                     Recovery studies are performed to know experimental procedure is free from
interference.  The  excipient  mixtures  used  such  as  Lactose  (5  gm),  Talc  (500  mg)  and
magnesium Stearate (100 mg).
                    To a accurately weighed amount of excipient a known amount of pure drug
nifedipine was added into a 50ml standard volumetric flask, then extracted with methanol and
dilution was made up to 50ml and filtered. 2ml of solution was pipetted into a 25ml standard
flask and the volume was made up with methanol.  The same procedure was repeated by
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changing  the  amount  of  pure  drug.  The  recovery  studies  were  performed  at  3  different
amounts of nifedipine spiked such as 20mg, 25mg and 30mg.
                    The standard solution was prepared by omitting the excipient mixture. The
dilution charts for 3 different spiking level and standard are shown as follows,
Dilution Chart For Recovery Studies For Nifedipine tablet :
a) Dilution For Standard :
0.02 gm of pure drug      *       50 ml
2 ml       *          25 ml
                   *               Methanol
b) Dilution for I spiking level (20mg) : 
0.02 gm of pure drug + 0.2 gm of excipient mixture        *       50 ml
                                                                                                   2ml      *         25 ml
c) Dilution for II spiking level (25 mg ):
0.025 gm of pure drug + 0.2 gm of excipient mixture           *       50 ml 
                                                                                                        2ml     *         25 ml
d) Dilution for III spiking level (30 mg ) :
0.03 gm of pure drug + 0.2 gm of excipient mixture        *        50 ml
      2ml      *        25 ml
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Table No. 24  Recovery Studies at I spiking level :
S. No Wt of std
(gm)
Abs of std Wt of drug
spiked to
excipient (g)
Absorbance
of test
% Recovery
    
     1
    
    
     
        0.0213
     
      
      0.414
      
    0.0212     0.416    100.95
    0.0216     0.418    99.56
    0.0218     0.419    98.88
Table No. 25  Recovery Studies at II spiking level :
S. No Wt of std
(gm)
Abs of std Wt of drug
spiked to
excipient (g)
Absorbance
of test
%Recovery
   
     1
   
   
       
       0.0219
       
        
        0.414
        
    0.0258      0.484       99.2
    0.0252      0.488       102.4
    0.0253      0.497       101.5
Table No. 26  Recovery Studies at III spiking level :
S. No Wt of std
(gm)
Abs of std Wt of drug
spiked to
excipient (g)
Absorbance
of test
%Recovery
   
     1
   
   
      
      0.0218
      
      
      0.408
      
    0.0304     0.576      101.2
    0.0306     0.574      100.2
    0.0306     0.574      100.2
ROBUSTNESS :
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            The Robustness is a measure of method capacity to remain unaffected by small,
deliberate variations in method parameters and provides an indication of method reliability
during normal use.
Change of Analytical wavelength:
                   The procedure for assay of nifedipine tablet was repeated by changing the
analytical  wavelength ± 3nm. The wavelength used to  measure the content  of  nifedipine
tablet was 327 nm, 330 nm and 333 nm respectively.
Table No. 27  Data for assay of Nifedipine tablet at 330 nm as wavelength :
S.
No
Wt of  Std
(gm)
Abs of std Wt of Test
(gm)
Abs of
test
Content of
tab (gm)
% Label
claim
1
   0.0203     0.414
   0.5500   0.489 0.00991 99.19
2    0.5501   0.497 0.01007 100.7
3    0.5500   0.496 0.01006 100.6
4    0.5502   0.489 0.00991 99.15
5    0.5500   0.496 0.01006 100.6
                                                                                                        % RSD = 0.84 %
Table No. 28  Data for assay of Nifedipine tablet at 327 nm as wavelength :
S. No Weight
of Std
(gm)
Absorbance
of Std
Weight of
tablet
powder
(gm)
Absorbance
of test
Content
of tablet
(gm)
%Label
Claim
1
  0.0200       0.404
 0.5500      0.485 0.01008 100.8
2  0.5503      0.486 0.01012 101.2
3  0.5500      0.481 0.01000 100
4  0.5502      0.495 0.01000 100
5  0.5500      0.476 0.00992 99.22
                                                                                                          % RSD = 0.77%
Table No. 29  Data for assay of Nifedipine tablet at  333 nm as wavelength :
S. No Weight
of Std
(gm)
Absorbance
of Std
Weight
of tablet
powder
Absorbance
of test
Content
of tablet
(gm)
%Label
Claim
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(gm)
1
 0.0200      0.404
0.5500    0.484 0.01008 100.8
2 0.5503    0.481 0.01002 100.2
3 0.5500    0.484 0.01008 100.8
4 0.5502    0.485 0.0101 101
5 0.5500    0.476 0.009922 99.22
                                                                                                        % RSD = 0.72%
RUGGEDNESS :
          Ruggedness can be defined as the intrinsic resistance to the influences excerted by
operational variable. The ruggedness of the method is the degree of precision of test results
obtained  by  analysis  of  the  samples  under  a  variety  of  normal  test  conditions,  such  as
different analysts, instruments and columns.
Change of Analyst :
The  procedure  for  assay  of  nifedipine  tablet  was  repeated  by  another  analyst  to
determine the  ruggedness of nifedipine tablet.
Table No. 30  Data for assay of Nifedipine tablet by another analyst :
Analyst I :
S.
No
Wt of  Std
(gm)
Abs of std Wt of Test
(gm)
Abs of
test
Avg Wt
(gm)
Content of
tab (gm)
% Label
claim
1
   0.0203     0.414
0.5500 0.489
 0.22753
0.00991 99.19
2 0.5501 0.497 0.01007 100.7
3 0.5500 0.496 0.01006 100.6
4 0.5502 0.489 0.00991 99.15
5 0.5500 0.496 0.01006 100.6
                                                                                                                   % RSD = 0.84%
Analyst II :
S.
No
Wt of  Std
(gm)
Abs of std Wt of Test
(gm)
Abs of
test
Avg Wt
(gm)
Content of
tab (gm)
% Label
claim
1
   0.0202     0.410
0.5502 0.497
 0.22753
0.010126 101.26
2 0.5500 0.499 0.010170 101.7
3 0.5504 0.497 0.010122 101.2
4 0.5501 0.491 0.010005 100.05
5 0.5500 0.496 0.010109 101.09
                                                                                                                  % RSD = 0.60%
Precision :
Dept. of Pharmaceutical Analysis  70
Chapter  6 Methodology
 Precision is  the measure of the degree of repeatability of analytical  method under
normal operation and is normally expressed as % RSD for the statistically significant number
of samples.
           Three terms are widely used to describe the precision of a set of replicate data
including SD, Coefficient of variation and standard error of  mean.
   Standard deviation (SD)=
xx
√∑¿ )2
                                                     n-1
Where ,
             x – Observed value
 x  - Arithmetic mean
             n – Number of observations
The square of standard deviation is called variance. The precision is assessed by co-efficient
of variation which is related to standard deviation.
  Coefficient of variation (% RSD )  = 
SD
x
x 100
Where ,
             SD – standard deviation
             X – Arithmetic mean
Standard Error of mean (SEM) = 
SD
√n
Where ,
       SD – standard deviation
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       n – Square root of number of observation
Table No. 31  Data for precision study
S. No Brand name Standard
Deviation
Coefficient of
variation
(%RSD)
Standard Error
of Mean (SEM)
    1 Nifedine     0.000084083       0.8406       0.0000376
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RESULTS AND DISCUSSION
Quencho fluorimetric determination of nifedipine using quinine sulphate as a Probe moiety
            Nifedipine is chemically dimethyl 1,4-dihydro 2-6-dimethyl 1-4-(2-nitrophenyl) pyridine-
3,5 dicarboxylate.  It  is  used as antianginal  and antihypertensive.  The molecule of nifedipine
contains  nitro  group  which  is  an  electron  withdrawing  group.  Therefore  it  can  quench  the
fluorescence  of  quinine  sulphate.  The  attempts  were  made  to  develop  quenchofluorimetric
method with quinine sulphate as  probe moiety.
            Quinine sulphate exhibits the fluorescence in 0.05M sulphuric acid and also in methanol.
Its fluorescence intensity was found to be linear in the concentration range of 0.1 – 0.5 µg/ml.
Quinine  sulphate  has  excitation  maxima  at  350  nm and  emission  maxima  at  450  nm.  The
excitation and emission wavelength were found from its activation and emission spectrum.
            The drug was mixed with the selected concentration of quinine sulphate to measure the
quenching. The concentration of quinine sulphate needed for the quenching study was fixed at
0.48 µg/ml from the calibration data. To obtain the linearity in quenching, the concentration of
nifedipine was selected in the concentration range of 4-20 µg/ml. The mixture containing quinine
sulphate with the concentration of 0.48 µg/ml with nifedipine conc ranging from 4-20 µg/ml
were excited at 350 nm and residual filuorescence was measured  at 450 nm. The quenching is
found to be linear for nifedipine in the range of 4-20 µg/ml.
            The assay of the nifedipine tablet was carried out. The average content of tablet was
0.010136g.
            The percentage recovery was found to be  98.2 % - 100.0 % from recovery studies. Hence
this  method  was  free  from interference and  accurate.  Accuracy of  the  assay method is  also
known by comparing the results of the proposed method with the assay result obtained from UV
spectrophotometric method. The % RSD for the fluorimetric assay 0.42 %.
The % RSD for UV spectrophotometric assay  0.8406 %.
                The method is robust which is known by carrying out the assay of tablet at different
excitation and emission wavelength slightly different from that of analytical wavelengths.
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The % RSD for assay of tablet at shorter wavelengths 0.85%  and at longer wavelengths 0.24%.
                The method has ruggedness which was determined by analysing the tablet formulation
by second analyst. The % RSD for analyst I was 0.42% and the % RSD for analyst II was found
to be 0.46%  respectively.
                The % RSD for all determinations assay of tablets, robustness, and ruggedness are
within the prescribed limits.
                 The LOD for the drug from calibration curve was found to be 0.03083 and LOQ was
found to be 0.093449.            
                Precision was computed from the assay value. % RSD was calculated and the value
was 0.42%  for assay of tablet. The data for precision study was given in table 17.
               The result of interference studies showed that the excipients present in the tablet
formulations have no effect in the quenching of fluorescence of probe moiety.
              The optimum condition for the fluorescence studies were also carried out to set the
concentration of quinine, desirable solvent,  pH and temperature condition.
              Hence this developed method can be used for routine analysis of nifedipine bulk powder
and its tablet formulation.
UV spectrophotometric Determination of nifedipine using Methanol
 Under  the  experimental  conditions  expressed,  calibration  curve,  assay  of  tablets,
recovery studies, change of wavelength, different analyst were performed. The nifedipine was
used as antihypertensive drug. Methanol was used as solvent.  Under the experimental conditions
the absorbance of nifedipine exhibited λ‐max at 240 nm and 330 nm. The longer wavelength has
been selected as the interference will be minimum at longer wavelength. The calibration curve
shows that Beer's law was obeyed in concentration range of 8-40 µg/ml. The assay of nifedipine
was carried out at analytical wavelength of 330 nm. The average content of nifedipine tablet was
0.00984g. Recovery studies were carried out at three different spiking levels 100%, 125%, and
150%  and % recovery ranged from 99.22-101.5%. The LOD and LOQ was found from the
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calibration curve of nifedipine.  LOD was found to be 0.0152114 and LOQ was found to be
0.0460952.
The precision was computed from the tablet assay and the % RSD was 0.84% and the
values are within the limit. The excipients did not exhibit any interference in assay of tablet
showing specificity of the method. The data for precision study was given in table 31.
     The method is robust which is known by carrying out the assay of tablet at different
wavelengths slightly different from that of analytical wavelengths.
    The % RSD for assay of tablet at shorter wavelengths 0.77% and at longer wavelengths
0.72% respectively.
    The method has ruggedness which was determined by analysing the tablet formulation
by second analyst. The % RSD for analyst I was 0.84% and the % RSD for analyst II was found
to be 0.60%  respectively.
                The % RSD for all determinations assay of tablets, robustness, and ruggedness are
within the prescribed limits. 
    Hence this developed method can be used for routine analysis of nifedipine tablet.
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CONCLUSION
              From the data obtained from the above result we concluded that the methods were very
simple  and  accurate.  When  compared  to  separation  techniques  such  as  chromatography  the
developed methods were simple cost  effective and adequately sensitive.  Hence the proposed
methods were found to be convenient and suitable for adopting analysis of nifedipine in bulk
drug and its formulation.
Nifedipine  was  selected  for  the  quenchofluorimetric  determination.  It  is  an  indirect
spectrofluorimetric  method. So different  fluorescent probe moieties could be adopted for  the
assay of the drug that has the quenching ability. Quinine sulphate was found to be suitable probe
moiety. The experimental conditions are as follows,
Excitation wavelength and emission wavelength were selected.
Determination of linearity range for the drug.
Checking the interference due to excipients in the assay procedure.
The  proposed  assay  procedure  is  validated  and  the  accuracy  of  the  method  was
established  from the  recovery  studies  and  also  by  comparing  the  results  with  the  alternate
analytical method being UV-Visible spectrophotometric method.
Precision of the method was tested by the reproducibility of the results and computition
of % RSD which is low.
Fluorescence method is being a sensitive analytical technique which has been adopted in
present work.
This method could be used in establishing the quality control of any formulation that
contain nifedipine.
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